

T1D is an incurable, life-threatening Disease...

8.4 MM patients worldwide 3% T1D incidence growth rate
... having severe complications

Takes away **12.2** years of life
X3 hospitalization rate

INSULIN IS NOT A CURE, IT IS DISEASE MAINTENANCE!

WE HAVE STRONG PATENT AND REGULATORY PROTECTION

- ✓ EU patent for Triple Therapy granted
- ✓ US patent for Triple Therapy granted ... and 4 new patents pending!
- ✓ 8-12 years of Exclusivities in USA and EU (NCE, ODE, PED)
- ✓ Accelerated Approval pathway
- ✓ 505B2



FDA WE RECEIVED SUCCESSFUL FEEDBACK FROM US FDA FOR PHASE 2A TRIALS!

WE ARE ON TRACK TO \$25MM SERIES A ROUND TO PROCEED WITH PHASE 2A CLINICAL TRIALS, AND FINAL FORMULATION DEVELOPMENT

OUR TRIPLE THERAPY: A combination of safe drugs in a ONCE DAILY ORAL PILL for T1D treatment and remission

PROOF-OF-CONCEPT IN PATIENTS!

EXPECTED EFFECTS OF COMBINATIONAL THERAPY

- REDUCE T1D complications**
- ONCE-A-DAY PILL**
- SUSTAINED normal blood glucose** levels
- SCALABLE** and **SAFE**
- STOPPING INSULIN** injections in recent-onset

SUCCESSFUL T1D RETROSPECTIVE STUDY IN ISRAELI CLINIC (19 PATIENTS):

- full remission in 70% of recent onset patients
- significantly increases C-peptide by 145%



PUBLISHED RESULTS OF STUDY IN 150 NOD MICE MODEL:

- Triple combination was significantly superior to all double-combinations



13.5MM global T1D patients by 2040
1.4MM conservative target for Levicure patients by 2040

MANAGEMENT TEAM



SHMUEL LEVIT
Founder & CMO, MD, PhD
Over 35 years clinical practice
Head of Endocrinology, Diabetes & Metabolism Institute, Assuta Medical Centers



MIKE TEILER
Chief Pharmaceutical Officer
Former VP Generic R&D, Teva
Former Group VP, Taro
Former VP Project Management Sun Pharma
35 years pharma experience



DANIIL KOSHELEV
CEO & co-Founder
Former CEO in biotech start-up
12 years executive and business development



YAFIT STARK
Head of Clinical Development, PhD
Former VP Head of Global Clinical Development, Teva
Former CCO of Innovative R&D, Teva
34 years Teva clinical development experience



LUCY KOSHELEVA
General Counsel & co-Founder
Former VP Investor relationship and legal (12-year experience)
Uppsala researcher



VALENTINE SUKHOVEEVA
CFO & Investor Relations
Former investment director at private equity fund
10+ years of project management roles



OLGA KARPINCHYK
Accounts & Operations
Executive at private medical center
Accounts and operational

ADVISORY PANEL



CHRIS HOWARD
Business Advisor, MSc, MBA
Former CCO and VP with 25 years of commercial leadership in life science & in vitro diagnostics
Executed multiple commercial builds
Led sale of IVD with above-market EBITDA multiple



ALEX RABINOVITCH
Scientific Advisor, MD, PhD
Former Prof. of Medicine and Director of the Diabetes Research at the University of Alberta
Honored with the Excellence in Clinical Research Award from JDRF, 140+ scientific articles



ALEXANDER FLEMING
Scientific/Regulatory Advisor, MD, PhD
Founder of Kinexum, a multi-faceted, strategic advisory firm, who led landmark FDA approvals of the first statin, insulin analog, metformin and other novel therapies
Represented FDA at ICH, WHO, and other initiatives



AMOS ANATOT
Strategic and Executive Advisor, Former CEO/COO in Global Food and Pharma
Former VP, Teva Europe
Former Executive VP, Frutarom
30 years top executive experience

LEVICURE

Our location: Israel, Rishon LeZion
Contact us: daniil@levicure.com
www.levicure.com